- PR Newswire•6 days agoCryoport and Database Integrations Launch Integrated Solution to Manage Patient and Manufacturer Schedules at Every Stage of the Clinical Trial Logistics Process
IRVINE, Calif., Sept. 22, 2016 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Company"), the world's leading cryogenic logistics company dedicated to the life sciences, today announced the integration of its proprietary logistics technology, the Cryoportal™, with Database Integrations, Inc.'s Integrated Cell Therapy Automated Network (iCAN) scheduling platform. The integration of these two platforms is designed to solve the challenges of manufacturing, distribution and global supply chain planning for the clinical development and commercialization of cell and gene therapy products. Cell and gene therapy processes start and end with the patient, requiring extensive and finely-tuned planning. Whether it is an autologous treatment (where the patient's cells are used to manufacture doses specific to that patient) or an allogeneic treatment (where patients receive cells originally collected from others) the overall logistics process poses specific challenges associated with the scheduling, storage and transporting of biologic commodities used in cell and gene therapy programs, especially the information appertaining thereto.
- PR Newswire•last month
LOS ANGELES, Aug. 22, 2016 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced financial results for the second quarter of 2016. Andrew Gengos, ...
ImmunoCellular Therapeutics, Ltd. (IMUC)
NYSE MKT - NYSE MKT Delayed Price. Currency in USD
|Bid||0.12 x 1400|
|Ask||0.12 x 10000|
|Day's Range||0.11 - 0.12|
|52wk Range||0.11 - 0.53|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-0.55|
|Avg Vol (3m)||2,823,934|
|Dividend & Yield||N/A (N/A)|